文献类型：期刊文献

英文题名：The effect and mechanism of erianin on the reversal of oxaliplatin resistance in human colon cancer cells

作者：Su, Chang[1];Liu, Shaoqun[1];Ma, Xiaoying[2,3];Liu, Jiajun[2,3];Liu, Jianwen[2,3];Lei, Ming[1];Cao, Yiou[1]

机构：[1]Fudan Univ, Minhang Hosp, Dept Surg, Shanghai 201199, Peoples R China;[2]East China Univ Sci & Technol, Sch Pharm, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China;[3]East China Univ Sci & Technol, Sch Pharm, Shanghai Key Lab New Drug Design, Shanghai 200237, Peoples R China

年份：2021

卷号：45

期号：12

起止页码：2420

外文期刊名：CELL BIOLOGY INTERNATIONAL

收录：;WOS:【SCI-EXPANDED(收录号:WOS:000685421500001)】；

基金：This study was supported by the Shanghai Municipal Health Commission (Grant no. 201840138).

语种：英文

外文关键词：colon cancer; drug resistance; erianin; oxaliplatin; P-gp; STAT3

摘要：Multidrug resistance (MDR) is the main cause of chemotherapy failure in the treatment of colon cancer and the high expression of drug efflux protein P-gp is one of the main factors of MDR. P-gp expression is regulated by the signal transducer and activator of transcription 3 (STAT3) signaling pathway. In this study, human colon cancer oxaliplatin-resistant cells were treated with oxaliplatin combined with the natural product erianin. Then, we evaluated the impact of erianin on drug resistance, and explored the relationship between erianin-related oxaliplatin resistance and the Janus kinase 2/STAT3 signaling pathway in vitro. Our research showed that erianin could significantly inhibit the proliferation of human colon cancer oxaliplatin-resistant cells, and suppress the cell cycle of oxaliplatin-resistant cells in the G2/M phase, indicating that erianin could regulate the MDR phenotype of oxaliplatin-resistant cells, and its mechanism might be the inhibition of STAT3 signaling pathway and the significant reduction of P-gp expression. However, this study provides a theoretical basis for the clinical application of erianin in platinum-based chemotherapy for colon cancer.